Galaxy watch finally takes your blood pressure in the us—six years late
The cuff you bought on Amazon in 2019 can stay in the drawer: Samsung has quietly unlocked blood-pressure monitoring for the Galaxy Watch 4 and newer in the United States, ending half a decade of regulatory purgatory that turned early adopters into involuntary beta testers.
The catch that keeps on giving
Every 28 days you will still need that old-school arm cuff to calibrate the watch, a ritual demanded by the FDA and conveniently omitted from Samsung’s glossy launch imagery. Miss the recalibration window and the sensor reverts to a expensive heart-rate monitor; the app simply stops displaying numbers. It is a bureaucratic tether, not a technical one, and it reminds you that even in 2025 the wrist remains the circulatory system’s least cooperative neighborhood.
The feature lands today via an update to the Samsung Health Monitor app, but only if your watch runs Wear OS 4+ and is paired with a Galaxy phone on Android 12 or higher. Non-Samsung handset owners are locked out—another FDA quirk—so your Pixel or OnePlus will keep pretending the sensor does not exist.
Why the wait felt endless
Samsung introduced the same optical hardware on the Galaxy Watch Active 2 back in 2020. Canadians got it within months; Europeans shortly after. Meanwhile, 119 million American adults with hypertension watched the feature orbit the planet like a taunting satellite. Community forums became support-group confessionals: users tracked shipping dates of Korean firmware, side-loaded APKs, begged Samsung for transparency. Silence. The company blamed “regulatory timelines,” but the calendar told a different story: Apple secured FDA clearance for its own, narrower hypertension notification in late 2025 without the same theatrical delay.
Apple’s approach is fundamentally passive: the Watch Series 10 looks for vascular-pattern anomalies and flags possible hypertension; it never spits out a mmHg value. Samsung gives you the raw numbers—systolic, diastolic, timestamped—data a cardiologist can actually use. The trade-off is the monthly cuff dance, but for anyone titrating medication or logging trends for a white-coat appointment, real numbers beat a probabilistic shrug.
Passive monitoring is next, says samsung
Later this year the company plans to roll out “passive” blood-pressure tracking, eliminating the need for deliberate measurements. Details remain murky—likely a cloud-side algorithm that ingests continuous pulse-wave data while you sleep—but the promise is 24-hour trend lines without lifting a finger. If the FDA signs off, Samsung could leapfrog Apple in usefulness while retaining the clinical-grade accuracy its rival deliberately avoids.
For now, the victory is partial: a feature that should have landed with the Watch 3 finally arrives on the Watch 8’s hardware. Early adopters who paid premium prices for unfinished tech deserve more than a push notification; they deserve an apology wrapped in a rebate. Instead they get a new calibration reminder every four weeks and the hollow satisfaction of being right all along.
Still, the numbers are now on your wrist, not in a Seoul server farm. For a country where cardiovascular disease kills one person every 33 seconds, belated access still counts—just don’t call it innovation. Call it catch-up with a cuff attached.